Joyce O’Shaughnessy, MD

Panelists discuss the key advice they would offer to fellow physicians, nurse practitioners, advanced practice providers, and pharmacists involved in the care of patients on capivasertib, emphasizing best practices for patient management and communication.

Panelists discuss their approach to monitoring and managing hyperglycemia in patients receiving capivasertib and providing education about it, including when to involve endocrinology and how management strategies may differ for patients with preexisting diabetes.

Panelists discuss the strategies they employ to manage adverse events in patients starting capivasertib, including minimizing the risk of diarrhea through dietary considerations and patient education, as well as approaches for monitoring and managing rash associated with the treatment and providing education about it.

Panelists discuss their clinical experiences with capivasertib, focusing on patient tolerability and the management of adverse effects associated with this targeted therapy.

Panelists discuss the findings of the CAPItello-291 trial, which investigated capivasertib combined with fulvestrant in advanced hormone receptor–positive, HER2-negative breast cancer, leading to its approval in November 2023 and highlighting its potential as a new targeted therapy option in the second-line setting due to the prevalence of PIK3CA, AKT1, and PTEN alterations.

Panelists discuss how aberrations in the PI3K/AKT/PTEN pathway drive treatment resistance and disease progression following first-line therapy in hormone receptor–positive, HER2-negative advanced breast cancer, emphasizing the critical role of repeat biomarker testing to guide ongoing treatment strategies and enhance patient outcomes.

Panelists discuss how to approach selecting first-line treatment options for hormone receptor–positive, HER2-negative advanced breast cancer by providing an overview of standard-of-care options and highlighting the primary considerations that guide treatment selection.

Panelists discuss how biomarker testing plays a critical role in hormone receptor–positive, HER2-negative advanced breast cancer, emphasizing the timing of testing, the relevance of specific genomic assays, and the significant impact on prognosis and treatment decisions.

Breast cancer specialists outline their institution’s practices regarding the choice between subcutaneous fixed-dose pertuzumab – trastuzumab-hyaluronidase and intravenous pertuzumab and trastuzumab.

Ian Krop, MD, PhD, outlines his institution’s approach to utilizing neoadjuvant therapy in patients with HER2+ early breast cancer, and Melinda Telli, MD, discusses the role of surgery.

A panel of experts on breast cancer provide insights on challenges encountered during the diagnosis of HER2+ early breast cancer and discuss the role of immunohistochemistry and FISH testing.

Closing their discussion, experts share ongoing studies utilizing genomic testing for patients with breast cancer.

Joyce O’Shaughnessy, MD and Erin Cobain, MD, offer their reflections of genomic testing in breast cancer and its impact on clinical practice.

Dr O’Shaughnessy and Dr Cobain review growing discussions from SABCS 2023 surrounding the impact of racial disparities and genomic testing for breast cancer patients.

Experts in breast cancer outline data presented at SABCS 2023, focusing on real-world evidence for genomic assays used in practice.

Dr. O’Shaughnessy details the genomic assay MammaPrint and how it compares to other multigene assays used in practice, highlighting the MINDACT and TAILORx trials.

Expert oncologists discuss genomic testing for patients with HER2-low breast cancer, noting the FLEX trial of MammaPrint and BluePrint.

A discussion on clinical considerations for genomic testing in patients with early-stage breast cancer.

Dr. O’Shaughnessy introduces MammaPrint and BluePrint, discussing their role in genomic testing for patients with breast cancer.

A comprehensive overview of genomic assays conducted for patients with early-stage breast cancer including MammaPrint, BluePrint, Oncotype DX.

Expert insights into the evolving therapeutic landscape for early-stage breast cancers, emphasizing targeted therapies and genomic testing for personalized treatment paradigms.

The panel closes their discussion by summarizing the most exciting recent advances in HER2+ breast cancer, the future of treatment, and unmet needs that must be addressed.